ABSTRACT
INTRODUCTION
Loss-of-function NF2/Merlin mutations are among the most frequent events driving malignant pleural mesothelioma (MPM), a rare cancer associated with asbestos exposure (1,2).
Biallelic NF2 mutations underlie Familial Neurofibromatosis Type 2 (NF2), characterized by debilitating nervous system tumors where treatment relies predominantly on surgeries or radiosurgery (3) . The prognosis of MPM is even bleaker as this cancer grows rapidly and is recalcitrant to both radio-and chemotherapy (4) . In contrast to some other cancers that can be effectively treated -although not cured -by targeted therapies, NF2-mutant tumors remain a therapeutic challenge owing to the lack of consensus on the molecular mechanisms that underlie their development and the absence of validated targets.
Complicating the outlook, increasing evidence suggests that Merlin is a multifunctional protein that shuttles between the cell cortex and the nucleus in a manner reminiscent but antithetic to that of the cell adhesion and signaling component β-catenin (5, 6) . At the cell cortex, Merlin interacts with the scaffold and signaling protein Angiomotin to suppress mitogenic signaling through Rac, thereby inhibiting PAK (7) . Merlin also regulates mitogenic signaling by suppressing mTORC1 in mesothelial, Schwann, and meningeal cells -tissues most commonly associated with NF2-mutant tumorigenesis (8, 9) . Although the mechanism by which Merlin suppresses mTOR signaling remains elusive, inactivation of NF2 confers sensitivity to rapalogs in bladder cancer and cetuximab-resistant lung cancer, suggesting that mTORC1 signaling broadly sustains the expansion of Merlin-deficient cancer cells (10, 11) . Recently, we discovered that the de-phosphorylated conformer of Merlin accumulates in the nucleus and suppresses tumorigenesis by inhibiting the cullin E3 ubiquitin ligase CRL4 DCAF1 (5) . Depletion of DCAF1
inhibited the hyperproliferation of schwannoma cells isolated from NF2 patients and suppressed the oncogenic potential of Merlin-mutant schwannoma and mesothelioma cell lines (5) . up on this hypothesis, we found that de-repressed CRL4 DCAF1 targets Lats1 and 2 for ubiquitylation and inhibition in the nucleus and thus activates YAP-driven transcription and oncogenesis. Analysis of clinical samples indicated that this oncogenic pathway is consistently activated in human NF2-mutant mesothelioma, schwannoma, and meningioma (12) . Despite these findings, the mechanisms governing Merlin's regulation of YAP remains under debate, due in part to potentially non-redundant mechanisms (6) .
Currently, multimodal therapy for MPM -including surgery and chemotherapy -extends patient survival by only a few months from the median survival of 1.5 years (4). Therefore, targeting of the oncogenic signaling pathways underlying aggressive NF2 loss-driven tumors -including those comprising a dominant fraction of MPM -would be of great clinical value. It was recently reported that NF2-mutant MPM is preferentially sensitive to a FAK inhibitor in pre-clinical models (13) ; however, clinical trials using a more selective FAK inhibitor were unable to demonstrate efficacy in NF2-mutant MPM (NCT01870609). Indeed, pre-clinical studies in mice using Nf2 loss-driven xenografts or autochthonous models have failed to completely suppress tumorigenesis using single or combination therapies, further highlighting the need for effective mechanism-based therapeutics (13) (14) (15) (16) (17) (18) .
Following our identification of CRL4 DCAF1 as a primary target of Merlin in the nucleus (5), we sought to obtain proof of principle that pharmacological inhibition of CRL4 DCAF1 could be effective in treating NF2-mutant tumors. Cullin E3 ligases, including CRL4 DCAF1 , are the bestcharacterized substrates of the ubiquitin-like modifier NEDD8. Neddylation of the cullin subunit at a conserved lysine residue promotes a conformational shift that fully activates ubiquitin ligase-conjugating activity by bringing target substrates into closer proximity with the ubiquitincharged E2 enzyme (19) (20) (21) . While multiple factors influence the activity of E3 ligasesincluding the abundance of adaptor modules -many E3 ligases display decreased ubiquitylation of target proteins upon depletion of active NEDD8 (22) . MLN4924 is a first-in-class inhibitor of the NEDD8 activating enzyme (NAE), blocking activation of NEDD8 and thereby depleting the pool of active NEDD8, which can be conjugated to target proteins (23) .
Importantly, a recent Phase I study of MLN4924 in patients with advanced solid tumors established efficient on-target inhibition of NAE, acceptable dose-limiting toxicities, and antitumorigenic activity in some patients (24) . Here we show that inhibition of CRL4 DCAF1 using MLN4924 sensitizes cells to traditional chemotherapy but displays limited pre-clinical activity even in combination with chemotherapy. However, combined inhibition of CRL4 DCAF1 and mTOR/PI3K almost completely suppresses the growth of NF2 loss-driven tumors.
MATERIALS AND METHODS

Animal Studies
Animal studies were conducted in accordance with protocols approved by the Institutional Membranes were incubated in blocking buffer (5% skim milk, 0.1% Tween, 10 mM Tris at pH 7.6, 100 mM NaCl) for 0.5-1 hour at room temperature and then with primary antibodies diluted in blocking buffer for another hour at the same temperature or overnight at 4°C. Antibodies and working concentrations are shown in Supplemental Table 1 . After three washes, the membranes were incubated with goat anti-Rabbit HRP-conjugated antibody (1:10,000; Santa NaCl, 40 mM NaF, 1 mM NaVO4, protease and phosphatase inhibitors) and subjected to SDS-PAGE and immunoblotting. Where indicated, densitometry analysis was performed using ImageJ software.
For extended materials and methods, see Supplemental Materials and Methods.
RESULTS
NEDD8 activating enzyme inhibition abrogates CRL4
DCAF1 activity and selectively blocks the proliferation of NF2-mutant schwannoma cells
Since CRLs are differentially sensitive to the effects of NAE inhibition (22), we set out to determine whether NAE inhibition abrogates the ubiquitin conjugating activity of CRL4 DCAF1 .
Preliminary experiments indicated that the fraction of CUL4 associated with DCAF1 is effectively de-neddylated by MLN4924 ( substrates of CRL4 DCAF1 , we conducted ubiquitylation assays with recombinant forms of Lats1 and 2. Importantly, MLN4924 administration inhibited Lats1 ubiquitylation as effectively as overexpression of Merlin (Fig. 1C) , a manipulation previously shown to inhibit CRL4 DCAF1 activity in vitro and in vivo (9) . In addition, MLN4924 treatment reduced the oligo-ubiquitylation of Lats2, although to a lesser extent than Merlin expression (Supplemental Fig. S1A , arrowhead).
Combined, these data suggest that MLN4924 blocks the inhibitory ubiquitylation of Lats1 and 2, potentially restoring inhibition of YAP.
Based on these in vitro findings, we sought to assess the preclinical efficacy of NAE inhibition in extent of DCAF1 depletion (Supplemental Fig. S2A and S2B ). These results confirm the potential therapeutic value of inhibiting CRL4 DCAF1 in NF2-mutant MPM.
As predicted, MLN4924 treatment caused a dose-dependent inhibition of cullin neddylation in NF2-mutant Meso-33 cells. Nearly complete inhibition was reached at 0.5 μM, confirming that this compound is capable of efficiently targeting cullin E3 ligases in MPM cells ( Fig. 2A) .
Notably, 0.5 μM MLN4924 induced phosphorylation of YAP at its inhibitory phosphorylation site Serine 127 to a similar extent -if not more efficiently -as compared to DCAF1 depletion ( treatment induced p27 expression (Fig. 2B) , which may contribute to cell cycle arrest (27) .
Indeed, at a concentration that almost completely blocks cullin neddylation, MLN4924 strongly induced cell cycle progression as demonstrated by suppression of the phosphorylation of Rb and Histone H3 (Fig. 2D ). These findings suggest that NAE inhibition in Merlin-deficient cells inhibits oncogenic YAP signaling and suppresses cell cycle progression. 
μM in 5 out of 7 NF2-mutant MPM lines, providing evidence that the large majority of NF2-mutant MPM lines are highly sensitive to MLN4924 (Fig. 2F) . MPM tumors and cell lines often have complex genotypes and a large fraction of them exhibit mutations not only in NF2 but also in CDKN2A, CDKN2B, and BAP1. Sensitivity to MLN4924 did not correlate with absence or presence of any of these additional genetic alterations in the MPM lines examined (2) . However, the NF2-mutant Meso-9 and Meso-10 lines have not been fully sequenced and it is therefore possible that their relative insensitivity to MLN4924 is due to an unidentified co-occurring genetic alteration. These findings are consistent with the model that NF2-mutant MPM cells are sensitive to MLN4924 because of its ability to inhibit oncogenic signaling through CRL4 DCAF1 (5) . (Fig. 3A) . Cisplatin-induced DNA damage also causes CDT1 degradation, which functions to halt the cell cycle as a result of DNA damage. MLN4924 stabilized CDT1
even in the presence of cisplatin -an effect of MLN4924 that has been shown to induce DNA re-replication and to contribute to further DNA damage and apoptosis (28, 29 
however, combining the compounds dramatically increased apoptosis, indicating that MLN4924 sensitizes NF2-mutant MPM cells to chemotherapy (Fig. 3B) .
To examine the ability of MLN4924 to sensitize NF2-mutant MPM cells to chemotherapy in vivo, we treated NOD-scid IL2Rgamma null (NSG) mice bearing VAMT or Meso-10 xenografts of approximately 100 mm 3 size with MLN4924, cisplatin + pemetrexed, or both. Both MLN4924 monotherapy and combination chemotherapy induced a statistically significant reduction in tumor growth (Fig. 3C and D) . However, combination therapy with MLN4924 and pemetrexed + cisplatin displayed significantly improved inhibition of tumor growth as compared to either individual treatment modality in both types of tumors ( Fig. 3C and D) . Individual and combined therapies were well tolerated (Supplemental Fig. S3A and S3B ). These preclinical data indicate that combining MLN4924 with first-line chemotherapy may improve the treatment NF2-mutant MPM.
Combined inhibition of NAE and mTOR/PI3K cooperate to block NF2-mutant tumor growth
Although MLN4924 inhibited tumor growth, especially in combination with chemotherapy, it did not completely suppress this event or cause tumor regression, suggesting that NF2 loss-driven tumorigenesis does not depend solely on CRL4
DCAF1
. Intriguingly, we had observed that treatment with MLN4924 or depletion of DCAF1 does not diminish mTORC1 signaling in NF2-mutant Meso-33 cells (Fig. 2A , B and C), suggesting that this oncogenic signaling pathway may provide a mechanism of resistance to inhibition of CRL4 (Fig. 4B) . Even in this genetically-defined Nf2-null cell line, DCAF1 depletion and MLN4924 administration did not affect mTORC1 signaling (Fig. 4B) , providing further support that Merlin regulates mTORC1 independently of CRL4 DCAF1 .
Based on these findings, we set out to test the hypothesis that combined inhibition of CRL4 DCAF1 and mTORC1 suppresses NF2-mutant MPM growth. We had shown that rapamycin inhibits the proliferation of NF2-mutant MPM lines to a greater extent than NF2-wild type lines (9) . In many tumor types, the therapeutic efficacy of rapalogs is limited by the release of mTORC1-mediated negative feedback loops that function to restrain AKT-mTOR signaling (9,33-37). Consistently, we found that treatment with rapamycin induces hyperactivation of both AKT and ERK in NF2-mutant MPM lines (Fig. 4C) . GDC-0980, a dual mTOR/PI3K inhibitor, was developed to block mTORC signaling while simultaneously suppressing feedback-regulated pathways (38).
Notably, GDC-0980 blocked mTORC1 signaling without activating Akt or ERK in VAMT and
Meso-33 ( Fig. 4D and Supplemental Fig. S4A ). Based on these results, we examined the preclinical efficacy of MLN4924 in combination with GDC-0980 in VAMT xenografts. Intriguingly, single agent therapy with GDC-0980 yielded marginally higher -albeit statistically insignificantefficacy relative to MLN4924 alone (Fig. 4E) . However, combination therapy with MLN4924 and GDC-0980 completely suppressed tumor growth (Fig. 4E ) and exceeded the efficacy of either single agent alone, standard first-line chemotherapy, and chemotherapy combined with MLN4924 with minimal toxicity (Fig. 3C, 3D and Supplemental Fig. S4E ). These findings support the concept that mTORC1 and CRL4 DCAF1 are essential and non-redundant oncogenic pathways sustaining NF2-mutant tumor growth, and their combined inhibition may be therapeutically efficacious.
To determine whether combined inhibition of NAE and mTORC1 could be broadly exploited as a rational therapy in NF2 loss-driven tumorigenesis, we evaluated the efficacy of MLN4924 and GDC-0980 in human schwannoma -the hallmark tumor of NF2 patients. Notably, MLN4924 suppressed the proliferation of primary human NF2-mutant schwannoma cells but did not affect that of NF2-WT Schwann cells (Fig. 4F) , providing genetic evidence that NF2-mutant tumor cells are selectively sensitive to MLN4924. Importantly, while GDC-0980 monotherapy inhibited NF2-mutant schwannoma to a similar extent as MLN4924, combination therapy significantly reduced the proliferation of these cells in vitro (Fig. 4G) , confirming the potential efficacy of dual inhibition of NAE and mTORC1 in NF2-mutant tumors.
Finally, we examined the efficacy of mTOR and NAE inhibition in an NF2-mutant epithelioid MPM patient-derived xenograft (PDX), MSK-LX19, in which we had identified a total loss of expression of Merlin by immunoblotting (Supplemental Fig. S4B ). Immunostaining and immunoblotting of small (≤200 mm 3 ) MSK-LX19 tumors grown in NSG mice and treated once with each drug singly and in combination confirmed that MLN4924 inhibits neddylation of cullins but does not appreciably affect mTORC1 signaling (Fig. 4H, 4I and Supplemental Fig. S4C ).
Conversely, GDC-0980 efficiently blocks mTORC1 signaling in vivo but does not affect neddylation of cullins. Similarly, MLN4924 induced stabilization of p27 while combination therapy significantly increased p27 expression (Supplemental Fig. S4D ), suggesting that MLN4924 and GDC-0980 cooperatively induce cell cycle arrest. Whereas MLN4924 or GDC-0980 monotherapy significantly reduced tumor growth (P<0.01 and P<0.001, respectively), MLN4924 and GDC-0980 combination therapy completely suppressed tumor growth (P<0.001) (Fig. 4J) . Combined, these data reveal that dual inhibition of CRL4 DCAF1 and mTORC1/PI3K
abrogates two critical oncogenic pathways sustaining the proliferation of NF2-mutant tumors and exhibit pre-clinical efficacy in both MPM and schwannoma models (Fig. 5) .
DISCUSSION
Incomplete understanding of the signaling circuits dysregulated by inactivation of Merlin has so far prevented the development of rational and effective therapies for NF2 and MPM. In this study, we found that inactivation of NAE using MLN4924 inhibits CRL4 DCAF1 -mediated 
Non-surgical therapies for NF2 tumors and NF2-mutant MPM are relatively ineffective in reducing morbidity and mortality. Our findings provide proof of principle that targeting oncogenic signaling pathways shared amongst NF2-mutant tumors, such as YAP and mTORC1, can radically alter disease progression. We anticipate that state-of-the-art mTORC1/2 inhibitors and forthcoming NAE inhibitors with improved pharmacokinetics/pharmacodynamics will be of great utility in treating NF2 loss-driven tumors.
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